Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00062582
First received: June 9, 2003
Last updated: May 4, 2012
Last verified: January 2012
  Purpose

The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
COPD
Drug: Roflumilast
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 Mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • pulmonary function.

Secondary Outcome Measures:
  • exacerbation rate
  • quality of life
  • symptoms
  • use of rescue medication
  • safety and tolerability.

Estimated Enrollment: 1000
Study Start Date: June 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Clinical diagnosis of COPD (Chronic Obstructive Pulmonary Disease)
  • Currently stable COPD with no change in COPD treatment in the prior 4 weeks

Main Exclusion Criteria:

  • Clinical diagnosis of asthma
  • Poorly controlled COPD
  • Regular need for daily oxygen therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00062582

  Hide Study Locations
Locations
United States, Alabama
ALTANA Pharma
Cities in Alabama, Alabama, United States
United States, Arizona
ALTANA Pharma
Cities in Arizona, Arizona, United States
United States, California
ALTANA Pharma
Cities in California, California, United States
United States, Colorado
ATLANA Pharma
Cities in Colorado, Colorado, United States
United States, Connecticut
ALTANA Pharma
Cities in Conneticut, Connecticut, United States
United States, Delaware
ALTANA Pharma
Cities in Delaware, Delaware, United States
United States, Florida
ALTANA Pharma
Cities in Florida, Florida, United States
United States, Georgia
ALTANA Pharma
Cities in Georgia, Georgia, United States
United States, Idaho
ALTANA Pharma
Cities in Idaho, Idaho, United States
United States, Indiana
ALTANA Pharma
Cities in Indiana, Indiana, United States
United States, Iowa
ALTANA Pharma
Cities in Iowa, Iowa, United States
United States, Kansas
ALTANA Pharma
Cities in Kansas, Kansas, United States
United States, Kentucky
ALTANA Pharma
Cities in Kentucky, Kentucky, United States
United States, Louisiana
ALTANA Pharma
Cities in Louisiana, Louisiana, United States
United States, Maryland
ALTANA Pharma
Cities in Maryland, Maryland, United States
United States, Michigan
ALTANA Pharma
Cities in Michigan, Michigan, United States
United States, Missouri
ALTANA Pharma
Cities in Missouri, Missouri, United States
United States, Nebraska
ALTANA Pharma
Cities in Nebraska, Nebraska, United States
United States, Nevada
ALTANA Pharma
Cities in Nevada, Nevada, United States
United States, New Jersey
ALTANA Pharma
Cities in New Jersey, New Jersey, United States
United States, New York
ALTANA Pharma
Cities in New York, New York, United States
United States, North Carolina
ALTANA Pharma
Cities in North Carolina, North Carolina, United States
United States, Ohio
ALTANA Pharma
Cities in Ohio, Ohio, United States
United States, Oregon
ALTANA Pharma
Cities in Oregon, Oregon, United States
United States, Pennsylvania
ALTANA Pharma
Cities in Pennsylvania, Pennsylvania, United States
United States, Rhode Island
ALTANA Pharma
Cities in Rhode Island, Rhode Island, United States
United States, South Carolina
ALTANA Pharma
Cities in South Carolina, South Carolina, United States
United States, Texas
ALTANA Pharma
Cities in Texas, Texas, United States
United States, Utah
ALTANA Pharma
Cities in Utah, Utah, United States
United States, Virginia
ALTANA Pharma
Cities in Virginia, Virginia, United States
United States, Washington
ALTANA Pharma
Cities in Washington, Washington, United States
United States, West Virginia
ALTANA Pharma
Cities in West Virginia, West Virginia, United States
Argentina
ALTANA Pharma
Cities in Argentina, Argentina
Canada
ALTANA Pharma
Cities in Canada, Canada
Colombia
ALTANA Pharma
Cities in Colombia, Colombia
Mexico
ALTANA Pharma
Cities in Mexico, Mexico
Peru
ALTANA Pharma
Cities in Peru, Peru
Sponsors and Collaborators
Takeda
Investigators
Principal Investigator: Douglas S. Helmersen, Prof. Dr. Peter Lougheed Center; 3500-26th Ave. NE, Calgary, Canada
  More Information

No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00062582     History of Changes
Other Study ID Numbers: BY217/M2-110
Study First Received: June 9, 2003
Last Updated: May 4, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Roflumilast
Chronic Obstructive Pulmonary Disease
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Signs and Symptoms, Respiratory
Respiratory Tract Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on October 20, 2014